Long-Term Benefits of Lifestyle and Metformin Interventions in Preventing Type 2 Diabetes

A comprehensive 21-year follow-up study from the U.S. Diabetes Prevention Program (DPP) has confirmed that both lifestyle modifications and metformin use provide sustained benefits in reducing the risk of developing type 2 diabetes. The DPP, which initially demonstrated a significant reduction in diabetes incidence, reports that the original intensive lifestyle interventions—focused on moderate weight loss and increased physical activity—cut the development of diabetes by 58% during the first three years. Meanwhile, metformin treatment resulted in a 31% reduction compared to placebo.

The recent long-term analysis, published in The Lancet Diabetes & Endocrinology, shows that the benefits of these interventions persisted over two decades. Participants who engaged in lifestyle changes experienced an extension of approximately 3.5 years without diabetes, while those on metformin saw an additional 2.5 years free of the disease. Notably, these advantageous effects were consistent across all racial and ethnic groups included in the study, highlighting the broad applicability of the interventions.

The trial involved adults at high risk for developing diabetes, with an average age of 51 at the start in 1996, and a significant portion identifying as minorities disproportionately affected by the condition. Despite challenges in maintaining long-term intervention adherence, even short-term efforts demonstrated long-lasting health benefits.

Currently, the Pennington Biomedical Research Center continues to follow participants enrolled in the study, emphasizing the enduring impact of early preventive strategies. As Dr. Owen Carmichael from Pennington Biomedical remarks, these findings could influence future public health approaches by illustrating that effective, sustained prevention of type 2 diabetes is achievable through lifestyle and medication, even over extended periods.

For more detailed insights, refer to the study: William C Knowler et al., Long-term effects and heterogeneity of lifestyle and metformin interventions on type 2 diabetes incidence over 21 years, The Lancet Diabetes & Endocrinology, 2025.